Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study

Lancet

Volumn 356, Issue 9227, 2000, Pages 359-365

  Hansson, Lennart ^a   Hedner, Thomas ^b   Lund Johansen, Per ^c   Kjeldsen, Sverre Erik ^d   Lindholm, Lars H ^e   Syvertsen, Jan Otto ^g   Lanke, Jan ^f   De Faire, Ulf ^h   Dahlöf, Björn ^b   Karlberg, Bengt E ⁱ  

^a UPPSALA UNIVERSITY   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^f LUND UNIVERSITY   (Sweden)

^g Varna Medical Centre   (Norway)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ABDOMINAL PAIN; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DYSPNEA; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MYALGIA; NORWAY; PRIORITY JOURNAL; SWEDEN; SYSTOLIC BLOOD PRESSURE; VERTIGO;

EID: 0034730027     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02526-5     Document Type: Article

References (23)

1. NORDIL Study Group. The Nordic Diltiazem Study: an intervention study in hypertension comparing calcium antagonist based treatment with conventional therapy. Blood Press 1993; 2: 312-21.
2. World Health Organization/International Society of Hypertension Fifth Mild Hypertension Conference. The 1989 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. J Hypertens 1989; 7: 689-93.
3. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328: 914-21.
4. Levy D. Left ventricular hypertrophy: epidemiological insights from the Framingham Heart Study. Drugs 1988; 35 (suppl 5): 1-5.
5. Levy D, Garrison RJ, Sagae DD Kännel W B, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-66.
6. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.
7. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA 1996; 275: 1507-13.
8. Jennings GL, Wong J. Reversibility of left ventricular hypertrophy and malfunction by antihypertensive treatment. In: Hansson L, Birkenhäger WH, eds. Handbook of hypertension, Vol 18: assessment of hypertensive organ damage. Amsterdam: Elsevier Science BV, 1997: 184-223.
9. Schmieder RE, Schlaich MP, Klingbeil AU, Martus P. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 1998; 13: 564-69.
10. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, part 2: short-term reductions in blood pressure-over-view of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38.
11. Gong L, Zhang W, Zhu Y, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14: 1237-45.
12. Staessen JA, Fagard R, Thijs L, et al, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-64.
13. Liu L, Wang JG, Gong L, Liu G, Staessen JA, for the Systolic Hypertension in China (Syst-China) Collaborative Group. Comparison of active treatment and placebo for older Chinese patients with isolated systolic hypertension. J Hypertens 1998; 16: 1823-29.
14. Hansson L, Lindholm LH, Ekbom T, et al, for the STOPHypertension-2 study group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension2 study. Lancet 1999; 354: 1751-56.
15. Hansson L, Hedner T, Dahlöf B. Prospective Randomized Open Blinded Endpoint (PROBE) study: a novel design for intervention trials. Blood Press 1992; 1: 113-19.
16. Hedner T, for the NORDIL Group. Progress report on the Nordic Diltiazem study (NORDIL): an outcome study in hypertensive patients. Blood Press 1999; 8: 296-99.
17. Lund-Johansen P, Omvik P. Effect of long-term diltiazem treatment on central haemodynamics and exercise endurance in essential hypertension. Eur Heart J 1990; 11: 543-51.
18. Grossman E, Messerli FH. Effect of calcium antagonists on plama norepinephrine levels, heart rate and blood pressure. Am J Cardiol 1997;80:1453-58.
19. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283: 1967-75.
20. Messerli FH. Implications of discontinuation of doxazosin arm of ALLHAT. Lancet 2000; 355: 863-64.
21. Staessen JA, Birkenhäger WH, Fagard RH. Dihydropyridine calcium-channel blockers for the treatment of hypertensive diabetic patients. Eur Heart J 2000; 21: 2-7.
22. Hansson L, Lindholm LH, Niskanen L, et al, for the Captopril Prevention Project (CAPPP) Study Group.Effect of angiotensinconverting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353: 611-16.
23. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-20.